ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer’s Disease Testing

ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer’s Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 – ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath’s proprietary phosphorylated Tau 217 (pTau217) antibody […]